Similar companies
Income Statement (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Gross Profit | -450,000 | 0.2% |
| Cost of Revenue | 450,000 | 0.2% |
| Operating expense | 45M | 23.4% |
| Net Income | -43M | 22.9% |
| EBITDA | -42M | 23.4% |
Balance Sheet (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Total Assets | 300M | 13% |
| Total Liabilities | 80M | 9% |
| Total Equity | 220M | 14.4% |
| Shares Outstanding | 61M | 0.3% |
Cash Flow (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Cash from operations | -41M | 16.9% |
| Cash from investing | 35M | 48.7% |
EPS
Financial Highlights for Pliant Therapeutics in Q2 '25
Gross Profit stood at -450,000, marking a 0.2% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 450,000, a -0.2% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 45M, showing a -23.4% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -43M, showing a 22.9% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -42M, showing a 23.4% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
The company's performance remained stable this quarter with no significant positive or negative changes in the key financial metrics.
